Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Study Details
Study Description
Brief Summary
Iron deficiency anemia affects over half of girls and young women with heavy periods and is the most common cause of anemia worldwide. Most girls with heavy periods who also have iron deficiency anemia are prescribed iron to take by mouth every day by their doctor. There are some studies showing that taking iron every other day may actually help the iron be absorbed into the bloodstream better. This study is trying to compare how taking iron every other day compares to taking iron daily for treatment of anemia.
The goal of this clinical research study is to learn which of the two methods of care will be the best way for girls and young women with iron deficiency anemia to take iron supplementation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
The research will be conducted at the following location(s):
Baylor College of Medicine, TCH: Texas Children's Hospital, and TCH: Texas Children's Hospital Clinic.
If patient appears to qualify for the study they will sign and date this consent form, and the doctor will confirm that they are eligible for the study. The patient will complete the following procedures:
-
Medical history including prior hospitalizations, lab results, medications, diet, social and family history
-
Physical Examination
-
Blood samples: The patient will not have any extra blood draws (pokes) for this study. However, we will ask to take about 1/2 (0.5) teaspoons (3 mL) of extra blood for an extra research test when you have follow up blood test(s) in one month.
Patient will be on the study for 24 weeks (6 months),and will receive an information sheet about how to take iron to help it absorb in the stomach and on iron-rich foods.
There are 2 different treatments in this study. If a patient enrolls, they cannot choose which treatment to receive. Instead, they will be randomly assigned to one of the two treatments. That means there is a fifty percent chance they will receive iron medicine to take every day and a fifty percent chance they will receive iron medicine to take every other day.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Daily Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning. |
Drug: Ferrous sulfate
Alternate day dosing of ferrous sulfate
Other Names:
|
| Experimental: Alternate Day Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning. |
Drug: Ferrous sulfate
Alternate day dosing of ferrous sulfate
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of eligible patients enrolled. [At enrollment]
Percentage of eligible patients who consent to be enrolled in the study. A secure screening and enrollment log will be kept. Each screened patient will be categorized as either: ineligible, eligible but not approached, eligible and enrolled, eligible and declined. If the latter (eligible and declined), the reason for declining will also be obtained and noted in the study log.
Secondary Outcome Measures
- Percentage of enrolled patients who agree to continue in the study after randomization [At enrollment]
Percentage of patients who continue in study as compared to total number of enrolled patients. Information will be obtained from the study log.
- Retention as measured by visit follow-up adherence [1 month, 3 months and 6 months after enrollment]
Percentage of enrolled patients that complete each follow up visit at the specified time points compared to the total number of enrolled patients.
- Adherence [3 months and 6 months after enrollment]
rate of adherence to medication in both arms based on returned medication volume concentration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 9 years or greater and less than age 22 years
-
Heavy menstrual bleeding, defined as a Pictorial Blood Assessment Chart (PBAC) Score
100
- Iron deficiency anemia, defined as both hemoglobin <12 g/dL and ferritin <15 ng/mL within 7 days of enrollment.
Exclusion Criteria:
-
non-uterine cause of vaginal bleeding
-
pregnancy
-
chronic kidney disease
-
serology confirmed celiac disease
-
active gastrointestinal blood loss
-
active malignancy
-
inability to follow-up at Texas Children's Hospital
-
receipt of intravenous iron within 30 days prior to enrollment
-
allergy or known inability to tolerate oral iron
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Texas Children's Pavilion for Women | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Baylor College of Medicine
Investigators
- Principal Investigator: Oluyemisi Adeyemi - Fowode, MD, Baylor College of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- H - 46363